MONTCLAIR, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180 Degree Capital”) today provides notice to its shareholders that the date of the previously announced special meeting of shareholders for the sole purpose of electing directors (“Director Election Special Meeting”) has been moved to September 15, 2025. This change of date resulted from constructive conversations with the shareholders who submitted a demand request on June 17, 2025 (the “Demand Letter”), who acknow ...

New AR/VR application empowers students to explore high-demand careers for the 2025–2026 school yearSAN JOSE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in immersive learning, invites educators and edtech innovators to Booth #1948 at ISTELive 25, held June 30–July 2 at the Henry B. González Convention Center. Attendees will experience the preview of the zSpace Career Explorer™ application, a groundbreaking augmented and virtual reality (AR/VR) tool ...

Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement WarrantsWATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has entered into a definitive agreement for the ...

Core Insights - The partnership between Richtech Robotics and Beijing City of Design Development Co., Ltd. aims to enhance AI integration with robotic solutions, focusing on service experiences in industries like hospitality, healthcare, and retail [2][3] - The collaboration will involve the establishment of a "Beijing Foreign-Invested R&D Center" to pursue advancements in domain-specific AI models, autonomous robotic decision-making systems, and integrated software-hardware platforms [7][2] - Richtech Robotics has deployed over 400 robotic solutions across various sectors in the U.S., including notable clients such as Texas Rangers' Globe Life Field and Hilton [3][4] Company Overview - Richtech Robotics specializes in collaborative robotic solutions for the service industry, aiming to transform customer experiences and enhance operational efficiency [4] - The company focuses on integrating advanced automation to improve interactions and drive innovation within organizations [4]

BEIJING, June 27, 2025 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced that the Company has increased its total net revenues and adjusted EBITDA (non-GAAP) guidance for the full year 2025."We were very pleased to deliver an impressive first quarter results, demonstrating sustained operating and financial momentum underpinned by strong strategic execution," said Qiyu Wang, Chief Fi ...

Total Revenue of $15.6 Million, a $5.7 Million or 58% Increase over Prior Year QuarterNet income of $0.9 Million, a $15.5 Million Increase over Prior Year QuarterAdjusted EBITDA of $4.0 Million, a $2.4 Million or 158% Increase over Prior Year QuarterTotal Fourth Quarter Direct Operating Margin of 55%LOS ANGELES, June 27, 2025 /PRNewswire/ -- Cineverse Corp. ("Cineverse" or the "Company") (NASDAQ: CNVS), a global streaming technology and entertainment company, today announced its financial results for its fo ...

BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day o ...

TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today it will issue its financial results for the three and six months ended June 30, 2025 after markets close on: Thursday, August 7, 2025 A conference call to discuss the results will be hosted by the CAPREIT senior management team on: Friday, August 8, 2025 at 9:00 am ET The telephone numbers for the conference call are: Canadian Toll Free: +1 (833) 950-0062Internatio ...

Core Insights - Ultragenyx Pharmaceutical Inc. has received Breakthrough Therapy Designation from the FDA for GTX-102 as a treatment for Angelman syndrome [1][2] - The designation highlights the urgent need for effective treatments and the promising clinical results observed with GTX-102 [2] - The Phase 3 Aspire study is currently enrolling participants, with plans for an additional Aurora study to evaluate GTX-102 in other genotypes and ages expected to start later in 2025 [3] Company Overview - Ultragenyx is a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases [7] - The company has a diverse portfolio of approved medicines and treatment candidates aimed at addressing high unmet medical needs [7] - Ultragenyx's management team has extensive experience in the development and commercialization of rare disease therapeutics [8] Product Information - GTX-102 (apazunersen) is an investigational antisense oligonucleotide therapy designed to reactivate expression of the UBE3A gene [4] - The therapy has received multiple designations from the FDA, including Orphan Drug Designation and Fast Track Designation [4] - The Phase 1/2 study demonstrated consistent developmental gains in 74 patients aged 4-17 with a full maternal UBE3A gene deletion [2] Angelman Syndrome Insights - Angelman syndrome is a rare neurogenetic disorder affecting approximately 60,000 people in commercially accessible geographies [5] - The disorder is characterized by cognitive impairment, motor impairment, and seizures, requiring continuous care for affected individuals [6] - There are currently no approved therapies for Angelman syndrome, but animal models suggest potential for symptom improvement at any age [6]

NOVI, Mich., June 27, 2025 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM) a global market leader of innovative thermal management and pneumatic comfort technologies, today announced the expansion of its long-standing partnership with DUOMED into France. Building on years of successful collaboration in the Benelux region, this extension marks a strategic milestone as both companies work to deliver advanced patient temperature management technologies to more clinicians and patients across Europe. Under this agre ...